<div id="readability-page-1"><p>Nebula Research &amp; Development LLC boosted its stake in shares of  Insmed, Inc. (NASDAQ:INSM - Free Report) by 985.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor  owned 36,661 shares of the biopharmaceutical company's stock after acquiring an additional 33,282 shares during the quarter. Nebula Research &amp; Development LLC's holdings in Insmed were worth $3,690,000 at the end of the most recent reporting period.</p><ul><li>Russell Rebalance: 3 Stocks Ready to Move Higher</li></ul><p>Other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of  Insmed during the 2nd quarter worth about $194,728,000.  Adage Capital Partners GP L.L.C. boosted its position in  Insmed by 109.2% during the first quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company's stock worth $262,967,000 after purchasing an additional 1,799,382 shares in the last quarter.  Nuveen LLC acquired a new stake in  Insmed in the first quarter valued at approximately $88,351,000.  Qube Research &amp; Technologies Ltd purchased a new stake in shares of  Insmed in the second quarter valued at approximately $108,898,000.  Finally, 1832 Asset Management L.P. acquired a new position in shares of  Insmed during the 1st quarter worth approximately $37,214,000. </p><h2>Insiders Place Their Bets</h2><p>In other news, insider Michael Alexander Smith sold 27,130 shares of Insmed stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $183.78, for a total transaction of $4,985,951.40. Following the completion of the sale, the insider directly owned 54,902 shares in the company, valued at $10,089,889.56. The trade was a 33.07% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, Director Melvin Md Sharoky sold 10,000 shares of the firm's stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $145.39, for a total value of $1,453,900.00. Following the transaction, the director owned 262,675 shares in the company, valued at approximately $38,190,318.25. This trade represents a 3.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 233,650 shares of company stock valued at $41,063,785 over the last 90 days. 3.00% of the stock is owned by corporate insiders. </p><h2>Insmed Stock Performance</h2><ul><li>Stock Rotation is Underway: Here are the Winners Moving Forward</li></ul><p>Shares of INSM stock opened at $189.85 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. The company's fifty day moving average price is $183.45 and its two-hundred day moving average price is $137.61. The firm has a market capitalization of $40.49 billion, a P/E ratio of -30.67 and a beta of 1.01. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75. </p><p>Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.35) by ($0.40). The firm had revenue of $142.34 million for the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The company's revenue for the quarter was up 52.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.27) earnings per share.  On average, research analysts anticipate that  Insmed, Inc. will post -4.56 earnings per share for the current fiscal year. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several equities research analysts recently commented on the stock. Cantor Fitzgerald began coverage on shares of Insmed in a report on Tuesday, October 28th. They issued an &#34;overweight&#34; rating and a $192.00 price target for the company. Royal Bank Of Canada boosted their price target on shares of Insmed from $139.00 to $215.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, October 31st. JPMorgan Chase &amp; Co. lifted their target price on Insmed from $111.00 to $135.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, August 20th. Stifel Nicolaus upped their target price on shares of Insmed from $121.00 to $145.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, August 14th. Finally, TD Cowen raised their target price on shares of Insmed from $223.00 to $231.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, November 20th. One research analyst  has rated the stock with a Strong Buy rating, twenty have issued  a Buy rating, one  has given a Hold rating and one  has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $194.26.</p><p><b>Check Out Our Latest Stock Report on Insmed</b></p><h2>About Insmed</h2> (Free Report)<p>Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Insmed</li><li>Insider Buying Explained: What Investors Need to Know</li><li>GameStop Looks Broken: Here’s Why GME Could Crash in 2026</li><li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li><li>Market Momentum: 3 Stocks Poised for Major Breakouts</li><li>How to Invest in Insurance Companies: A Guide </li><li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li></ul><p><strong>Want to see what other hedge funds are holding INSM?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Insmed Right Now?</h2><p>Before you consider Insmed, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.</p><p>While Insmed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

INSM

<p>Nebula Research & Development LLC increased its stake in Insmed, Inc. by 985% in Q2, now holding 36,661 shares worth $3.69 million. Other investors also adjusted their positions. Insmed's stock performance showed a 52.4% revenue increase YoY, despite a Q3 EPS loss of $1.75. Analysts have given positive ratings, with price targets ranging from $135 to $215.</p>

Insmed, Inc. $INSM Shares Acquired by Nebula Research & Development LLC